1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.

Clinical transplants

Volumn , Issue , 2010, Pages 405-407

  Shapiro, R ^a   Lunz, J ^b   Zeevi, A ^b   Basu, A ^b   Mapara, M ^b   Randhawa, P ^b   Tan, H P ^b   Sharma, V ^b   Humar, A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BORONIC ACID DERIVATIVE; BORTEZOMIB; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ARTICLE; BK VIRUS; BLOOD; CASE REPORT; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; PATHOGENICITY; POLYOMAVIRUS INFECTION; TIME; TREATMENT OUTCOME; VIROLOGY;

BK VIRUS; BORONIC ACIDS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MIDDLE AGED; POLYOMAVIRUS INFECTIONS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960056859     PISSN: 08909016     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)